VJHemOnc is committed to improving our service to you

ESH MM 2018 | MRD sequencing test approved for MM in the US

VJHemOnc is committed to improving our service to you

Nikhil Munshi

Nikhil Munshi, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the prospects for measurable residual disease (MRD) testing following the recent FDA approval of a deep sequencing-based technique for MRD detection in multiple myeloma (MM). This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter